AC Immune's Upcoming Presentation at Major Healthcare Conference
AC Immune SA (NASDAQ: ACIU), a leading clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative diseases, has exciting news. The company will participate at the Jefferies 2025 London Healthcare Conference, a prominent event in the healthcare industry.
Details of the Event
The Jefferies Global Healthcare Conference will take place from November 17 to 20 in London, providing an excellent opportunity for AC Immune to connect with investors and industry experts. During the conference, AC Immune's management team will engage in a fireside chat and one-on-one investor meetings, effectively sharing insights into the company's innovative approaches.
Fireside Chat Schedule
Mark your calendars! The fireside chat is scheduled for November 18, 2025, at 4:30 AM (ET) / 9:30 AM (GMT). It promises to be an exciting session where the management will discuss the latest advancements in AC Immune’s research and drug developments. Those unable to attend in person can access a live webcast of the discussion on the company’s website, and a replay will be available afterward.
Investment Opportunities
With a commitment to fighting neurodegenerative diseases such as Alzheimer's and Parkinson's, AC Immune is paving the way in the biopharmaceutical sector. The company boasts a robust pipeline fueled by two clinically validated technology platforms—SupraAntigen and Morphomer. These platforms support a range of therapeutic and diagnostic programs, currently advancing through Phase 2 and Phase 3 trials.
Strategic Partnerships and Future Prospects
AC Immune has successfully established strategic partnerships with several leading global pharmaceutical companies, resulting in significant non-dilutive funding for their innovative programs. This collaboration has the potential to yield over $4.5 billion in milestone payments and royalties, signifying the strong market interest in their therapeutic offerings.
About AC Immune
AC Immune SA is recognized for its pioneering efforts in precision prevention for neurodegenerative diseases caused by misfolded proteins. Their commitment to understanding these complex diseases has positioned them as a global leader in the field. Through their advanced research, AC Immune is not only enhancing diagnostics but also working towards groundbreaking treatments that offer hope to millions affected by these conditions.
Contact Information
For more details about their participation at the conference or to arrange meetings, individuals should reach out to AC Immune’s team. Gary Waanders, Ph.D., MBA, serves as the Senior Vice President of Investor Relations and Corporate Communications. Interested parties can contact him via phone at +41 21 345 91 91 or email at gary.waanders@acimmune.com. Additionally, International Media inquiries can be directed to Chris Maggos at Cohesion Bureau by calling +41 79 367 6254 or emailing chris.maggos@cohesionbureau.com.
Frequently Asked Questions
What is the Jefferies 2025 London Healthcare Conference about?
The conference is a significant event that gathers healthcare industry leaders, investors, and innovators to discuss advancements and share insights in healthcare.
When will AC Immune's fireside chat take place during the conference?
The fireside chat is scheduled for November 18, 2025, at 4:30 AM (ET) / 9:30 AM (GMT).
How can I access the webcast of AC Immune's presentation?
The webcast will be available on AC Immune's website during the conference, with a replay accessible afterward.
What is AC Immune's focus in biopharmaceuticals?
AC Immune is focused on pioneering precision therapeutics aimed at neurodegenerative diseases, utilizing innovative technologies and collaborative partnerships.
Who can I contact for more information about AC Immune?
For details about their participation in the conference, you can contact Gary Waanders at gary.waanders@acimmune.com or call +41 21 345 91 91.